Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Stock Information for Athira Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athira Pharma Inc.

Ensysce Biosciences Reports First Quarter 2025 Financial Results
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.